Sanofi and Boao Lecheng International Medical Tourism Pilot Zone Sign Strategic Cooperation Memorandum
Sanofi
Pharmaceutical R&D Developer
Lecheng Pilot Zone
On February 28, 2013, the State Council approved the establishment of the Boao Lecheng International Medical Tourism Pilot Zone, granting a series of medical opening-up policies. The Pilot Zone is located on both sides of the Wanquan River, between the Jiage Town urban area of Qionghai City and the core area of the Boao Forum. Its planned scope extends from the East Ring Railway in the northwest to Lecheng Island in the southeast, with a north-south distance of approximately 10 kilometers. Covering a total area of 20.9 square kilometers, its planned construction land area is 10.64 square kilometers. It aims to become an international medical tourism destination, a base for cutting-edge medical technology research, development, and transformation, a gathering place for new national medical institutions, a clinical medical center with distinctive features and advanced technology, a traditional Chinese medicine rehabilitation center, an international-standard health examination center, a showcase and follow-up treatment center for internationally renowned medical institutions in China, a clinical medical center for rare diseases, and an international medical exchange center — "three bases and six centers."
Shanghai, November 9, 2020 /PRNewswire/ -- At the Sanofi booth during the Third China International Import Expo, French pharmaceutical company Sanofi Group held a strategic cooperation signing ceremony with the Administration of Boao Lecheng Pilot Zone. Gu Gang, Secretary of the Party Committee and Director of the Administration of Boao Lecheng International Medical Tourism Pilot Zone; Pius Hornstein, General Manager of Sanofi's Global General Medicines Business Unit in China and President of Sanofi China; and Wang Baikang, General Manager of Sanofi's Global Specialty Care Business Unit in China, attended and witnessed the signing ceremony.
Representatives of the Boao Lecheng Pilot Zone of International Medical Tourism Administration and Sanofi China Sign Strategic Cooperation Memorandum
Sanofi’s collaboration with the Boao Lecheng Pilot Zone covers multiple areas, including the “Never-Ending Exhibition of Pharmaceuticals and Medical Devices,” pilot implementation of innovative drugs and vaccines, real-world data research, and the Lecheng Global Special Drug Insurance. Both parties will leverage their respective unique advantages to commit to bringing more globally innovative and clinically urgent high-quality medicines to China, thereby enhancing access to premium innovative medical products and services while improving diagnostic and therapeutic quality and healthcare affordability.
Gu Gang, Director of the Lecheng Pilot Zone Administration Bureau, stated: “Lecheng boasts unique policy advantages, and Sanofi has a robust pipeline of products under development. The collaboration between the two is not only expected to accelerate the introduction of innovative overseas drugs into Lecheng, but will also, through‘“Specialty Drug Insurance” and other insurance products address the issue of drug affordability, with the ultimate goal of benefiting patients by ensuring they have access to necessary medications and can afford them.
Zhu Hailuan, Vice President of Public Affairs and Market Access at Sanofi China, stated, “The signing of this strategic cooperation agreement marks a new milestone in our partnership, building upon our previous collaborations. Moving forward, leveraging the unique breakthrough policies of the Lecheng Pilot Zone, Sanofi will more actively promote the introduction and use of its globally leading innovative medicines and vaccines in the zone, thereby benefiting more Chinese patients and contributing to the Healthy China 2030 initiative.”
Address by Dr. Thomas Hudson, President of Sanofi China
Sanofi’s collaboration with Lecheng began more than a year ago. In December 2019, Sanofi established its presence in the Lecheng Pilot Zone, setting up the first real-world study center for a multinational enterprise in Lecheng. Over the past year, Sanofi has implemented multiple projects in Lecheng, including the targeted biologic agent Dupixent for the treatment of atopic dermatitis, which was made available at the Boao Lecheng Super Hospital prior to its official market launch, thereby benefiting Chinese patients at an earlier stage.
Liu Zhefeng, Deputy Director of the Administrative Bureau of Boao Lecheng Pilot Zone for International Medical Tourism; Li Wenxiu, Deputy Director of the Health Commission of Boao Lecheng Pilot Zone for International Medical Tourism; Liu Hongtao, Deputy Director of the Drug Administration of Boao Lecheng Pilot Zone for International Medical Tourism; and other officials attended the signing ceremony.